AP NEWS

Global Statin Market (2019-2023) is Forecast to Register a CAGR of Over 2% - ResearchAndMarkets.com

December 7, 2018

DUBLIN--(BUSINESS WIRE)--Dec 7, 2018--The “Global Statin Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The statin market will register a CAGR of over 2% by 2023.

The increasing statin use will help the market grow at a steady rate. In the US and the UK, people aged 40 and above are recommended to monitor their cholesterol level. Statins are considered an evidence-based treatment for high risk patients with elevated cardiovascular disorder.

Rising prevalence of hypercholesterolemia

The rising prevalence of hypercholesterolemia is fueling the demand for generic cholesterol medications. Cardiovascular disease is one of the primary causes of mortality in Western countries.

Fierce generic competition

Patient expiration is a major challenge for companies developing branded drugs as it provides an opportunity for the development of generic drugs.

Key Players

AstraZeneca Merck Novartis Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis Pipeline

PART 04: MARKET SIZING

Market definition Market sizing 2018 Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type Comparison by type Synthetic statins - Market size and forecast 2018-2023 Natural statins - Market size and forecast 2018-2023 Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: MARKET SEGMENTATION BY APPLICATION

Dyslipidemia Others

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation Geographic comparison Americas - Market size and forecast 2018-2023 EMEA - Market size and forecast 2018-2023 APAC - Market size and forecast 2018-2023 Key leading countries Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

Overview Landscape disruption

PART 14: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors AstraZeneca Merck Novartis Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/nv3v3x/global_statin?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181207005430/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/07/2018 12:49 PM/DISC: 12/07/2018 12:49 PM

http://www.businesswire.com/news/home/20181207005430/en

AP RADIO
Update hourly